Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7357154 | 1.00 | ECE1 (0.40) | ECE1CA2CA1SCN9ACYP3A4 | |
| SCHEMBL16886886 | 1.00 | ECE1 (0.40) | ECE1CA2CA1SCN9ACYP3A4 | |
| SCHEMBL18199346 | 0.86 | ALDH1A1 (0.39) | SCN9ACYP3A4CYP2C19ITGB3ITGA2B | |
| SCHEMBL3977107 | 0.86 | ECE1 (0.44) | ECE1CA2CA1ITGB3ITGA2B | |
| SCHEMBL18199349 | 0.86 | ALDH1A1 (0.39) | SCN9ACYP3A4CYP2C19ITGB3ITGA2B | |
| SCHEMBL18199347 | 0.86 | ALDH1A1 (0.39) | SCN9ACYP3A4CYP2C19ITGB3ITGA2B | |
| SCHEMBL20335048 | 0.86 | ECE1 (0.44) | ECE1CA2CA1ITGB3ITGA2B | |
| SCHEMBL3977104 | 0.86 | SCN9A (0.36) | CA2CA1SCN9ACYP3A4CYP2C19 | |
| SCHEMBL20335047 | 0.86 | ECE1 (0.44) | ECE1CA2CA1ITGB3ITGA2B | |
| SCHEMBL12069014 | 0.81 | SCN9A (0.34) | CA2CA1SCN9ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005448-A2 | NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS | Du Pont Pharmaceuticals Company (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999009000-A2 | NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| US-9902726-B2 | Pyridone-sulfone morphinan analogs as opioid receptor ligands | PURDUE PHARMA L.P. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160318932-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2016-11-03 | — | — | US | disclosed |
| WO-2015102682-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | PURDUE PHARMA L.P. (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-1005448-A2 | NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS | Du Pont Pharmaceuticals Company (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999009000-A2 | NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318932-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | OPRK1, OPRM1, OPRL1 | ECE1 1929/4885CA2 4457/4885CA1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.